LURASIDONE SHOULD NOT BE USED CONCOMITANTLY WITH A STRONG OR MODERATE CYP3A4 INHIBITOR (E.G., KETOCONAZOLE, CLARITHROMYCIN, RITONAVIR, VORICONAZOLE, MIBEFRADIL, DILTIAZEM, ATAZANAVIR, ERYTHROMYCIN, FLUCONAZOLE, VERAPAMIL ETC., ELSE ITS DOSE SHOULD BE REDUCED TO HALF OF THE ORIGINAL DOSE LEVEL.
GRAPEFRUIT AND GRAPEFRUIT JUICE SHOULD BE AVOIDED IN PATIENTS TAKING LURASIDONE, SINCE THESE MAY INHIBIT CYP3A4 AND ALTER ITS CONCENTRATIONS.
LURASIDONE SHOULD NOT BE USED CONCOMITANTLY WITH A STRONG OR MODERATE CYP3A4 INDUCER (E.G., RIFAMPIN, AVASIMIBE, ST. JOHN'S WORT, PHENYTOIN, CARBAMAZEPINE, ETC.) ELSE IT MAY BE NECESSARY TO INCREASE ITS DOSE.
NO DOSAGE ADJUSTMENT IS REQUIRED WHEN ADMINISTERED CONCOMITANTLY WITH LITHIUM, VALPROATE, OR SUBSTRATES OF P-GP OR CYP3A4